Business Context and Reporting Period
Company: BioMarin Pharmaceutical Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 28, 2024
Event: Entry into a Material Definitive Agreement (Credit Agreement).
Key Financial Metrics and Debt Structure
This filing details the establishment of a new credit facility rather than reporting operational financial results (revenue, profit, or cash flow) for a specific period.
- Facility Type: Revolving Credit Facility.
- Total Commitment: Up to $600 million.
- Amount Drawn at Closing: $0 (None drawn).
- Maturity Date: August 28, 2029.
- Interest Rate Structure: Floating rate based on Term SOFR, Base Rate, EURIBOR, or SONIA plus a margin ranging from 112.5 bps to 175 bps, dependent on the Company's total net leverage ratio.
- Unused Line Fee: Ranges from 12.5 bps to 20 bps per annum, payable quarterly.
Material Changes and Purpose
The primary material change is the execution of the Credit Agreement with Citibank, N.A., as Administrative Agent. The Company intends to use the proceeds from this facility to finance ongoing working capital needs and for other general corporate purposes. No prior comparable period data is provided in this filing as it is a transactional report.
Guidance, Risks, and Covenants
Covenants and Restrictions: The agreement includes customary covenants restricting the Company's ability to incur additional indebtedness, dispose of assets, incur liens, make investments, and pay dividends or distributions, subject to specified exceptions.
Events of Default: Includes failure to make timely payments, non-compliance with covenants, insolvency or bankruptcy events, cross-default to other material indebtedness, and a "change of control."
Remedies: Upon an event of default, lenders may terminate commitments, stop credit extensions, and accelerate outstanding obligations.
Prepayment: The Company has the right to prepay the facility in whole or in part without premium or penalty.
Investor Verification Checklist
- Verify the Company's current total net leverage ratio to determine the applicable interest rate margin (112.5 bps to 175 bps).
- Review the specific exceptions to the covenants regarding dividends and additional indebtedness in the full Credit Agreement (Exhibit 10.1).
- Monitor future 10-Q or 10-K filings to track actual utilization of the $600 million facility.
- Confirm the impact of the unused line fee on quarterly cash flow if the facility remains undrawn.